JP2001525816A5 - - Google Patents

Download PDF

Info

Publication number
JP2001525816A5
JP2001525816A5 JP1998548911A JP54891198A JP2001525816A5 JP 2001525816 A5 JP2001525816 A5 JP 2001525816A5 JP 1998548911 A JP1998548911 A JP 1998548911A JP 54891198 A JP54891198 A JP 54891198A JP 2001525816 A5 JP2001525816 A5 JP 2001525816A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1998548911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001525816A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB1998/001343 external-priority patent/WO1998051344A1/en
Publication of JP2001525816A publication Critical patent/JP2001525816A/ja
Publication of JP2001525816A5 publication Critical patent/JP2001525816A5/ja
Withdrawn legal-status Critical Current

Links

JP54891198A 1997-05-12 1998-05-12 治療における腫瘍壊死因子アルファおよび血管内皮成長因子の抑制 Withdrawn JP2001525816A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85488197A 1997-05-12 1997-05-12
US08/854,881 1997-05-12
PCT/GB1998/001343 WO1998051344A1 (en) 1997-05-12 1998-05-12 Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy

Publications (2)

Publication Number Publication Date
JP2001525816A JP2001525816A (ja) 2001-12-11
JP2001525816A5 true JP2001525816A5 (cg-RX-API-DMAC7.html) 2005-12-02

Family

ID=25319772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54891198A Withdrawn JP2001525816A (ja) 1997-05-12 1998-05-12 治療における腫瘍壊死因子アルファおよび血管内皮成長因子の抑制

Country Status (6)

Country Link
EP (2) EP0980258A1 (cg-RX-API-DMAC7.html)
JP (1) JP2001525816A (cg-RX-API-DMAC7.html)
AU (1) AU7345798A (cg-RX-API-DMAC7.html)
CA (1) CA2290021A1 (cg-RX-API-DMAC7.html)
HK (1) HK1044887A1 (cg-RX-API-DMAC7.html)
WO (1) WO1998051344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2064915C (en) 1989-08-07 2001-05-29 Deborah A. Rathjen Tumour necrosis factor binding ligands
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
EP1049773B1 (en) 1998-01-22 2007-07-25 Btg International Limited Inhibition of cytokine production
CA2364026C (en) * 1999-03-02 2012-08-21 Centocor, Inc. Anti-tnf.alpha. antibodies in therapy of asthma
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7687461B2 (en) 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
WO2001064889A2 (en) * 2000-03-02 2001-09-07 Xencor Tnf-alpha variants for the treatment of tnf-alpha related disorders
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20040136991A1 (en) * 2002-07-19 2004-07-15 Abbott Biotechnology Ltd. Treatment of anemia using TNFalpha inhibitors
AU2003228509B2 (en) 2002-10-15 2008-06-26 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
WO2005041877A2 (en) * 2003-10-29 2005-05-12 Children's Medical Center Corporation Method of inhibiting rejection following organ transplantation
AP2006003619A0 (en) 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
EP1885397A4 (en) 2005-05-16 2010-01-20 Abbott Biotech Ltd USE OF A TNF HEMMER FOR THE TREATMENT OF EROSIVE POLYARTHRITIS
JP2008120722A (ja) * 2006-11-10 2008-05-29 Benesis Corp 生物由来製品の偽薬
EP4427737A3 (en) * 2009-03-20 2024-11-20 Antares Pharma, Inc. Hazardous agent injection system
EP2704835A4 (en) 2011-05-06 2014-12-24 Bio Rad Laboratories THERMOCYCLE COMPRISING A STEAM CHAMBER FOR RAPID TEMPERATURE CHANGES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1097945B1 (en) * 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
JP3398382B2 (ja) * 1992-10-28 2003-04-21 ジェネンテク,インコーポレイテッド 血管内皮細胞増殖因子アンタゴニスト
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists

Similar Documents

Publication Publication Date Title
JP2000507042A5 (cg-RX-API-DMAC7.html)
JP2000509635A5 (cg-RX-API-DMAC7.html)
JP2000509912A5 (cg-RX-API-DMAC7.html)
JP2000509942A5 (cg-RX-API-DMAC7.html)
JP2000510751A5 (cg-RX-API-DMAC7.html)
JP2000507369A5 (cg-RX-API-DMAC7.html)
JP2000507433A5 (cg-RX-API-DMAC7.html)
JP2000508866A5 (cg-RX-API-DMAC7.html)
JP2000510793A5 (cg-RX-API-DMAC7.html)
JP2000508022A5 (cg-RX-API-DMAC7.html)
JP2000508841A5 (cg-RX-API-DMAC7.html)
JP2001515546A5 (cg-RX-API-DMAC7.html)
JP2001514552A5 (cg-RX-API-DMAC7.html)
JP2000509853A5 (cg-RX-API-DMAC7.html)
JP2002503177A5 (cg-RX-API-DMAC7.html)
JP2001527597A5 (cg-RX-API-DMAC7.html)
JP2001525816A5 (cg-RX-API-DMAC7.html)
JP2000510969A5 (cg-RX-API-DMAC7.html)
JP2000510247A5 (cg-RX-API-DMAC7.html)
JP2002501484A5 (cg-RX-API-DMAC7.html)
JP2002506477A5 (cg-RX-API-DMAC7.html)
JP2000508836A5 (cg-RX-API-DMAC7.html)
JP2000508102A5 (cg-RX-API-DMAC7.html)
JP2002510991A5 (cg-RX-API-DMAC7.html)
JP2000509818A5 (cg-RX-API-DMAC7.html)